Artivion Inc

AORTNYSE · USD
23.78USD-0.35 (-1.45%)
255

Artivion Inc (AORT) Covered Calls

As of September 22, 2026, AORT has 4 covered call opportunities in the coming three months. Return ranges from 6.0 to 27.2% until expiration. Annualized return ranges from 15.4 to 47.9%. The nearest expiration is November 20, 2026. Maximum potential profit is $642.

Read more

Running AORT covered calls helps you generate consistent income from Artivion Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Artivion Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best AORT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if AORT stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling AORT covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Artivion Inc covered call is worth writing.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system.

In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Income-focused investors, long-term AORT holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling AORT covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Artivion Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV percentile48.02% Neutral
  • Market cap (M$)1,176
  • 52 weeks high-49.99%
  • 52 weeks low25.94%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$42.15
    77.25% above the current stock price
  • Dividend
  • Payout ratio0.00%
  • Earnings date2026-11-05
  • P/E
  • Future P/E83.57
  • EPS (ttm)-0.07
  • EPS growth next 5 years30.11%

As of September 22, 2026

2027-04-1620730.0026.960.054.90642.0027.1747.91-0.21+0.4104.85
2027-01-1511625.005.801.802.55317.0013.4242.21-7.62+0.49360.75
2026-11-206025.005.800.054.80142.006.0136.56-0.21+0.5004.75
2027-04-1620725.005.800.704.90207.008.7615.45-2.96+0.5324.20

As of September 22, 2026

Sell covered calls with the data behind you

Find the best AORT covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial